Skip to main content
SpringerLink
Log in
SpringerLink
Log in

Adjuvant Therapy Following Surgery for Primary Malignant Melanoma

  • Chapter
Malignant Melanoma 1

Part of the book series: Cancer Treatment and Research ((CTAR,volume 9))

Abstract

Adjuvant therapy following surgical resection of primary malignant tumors has become an important consideration in the treatment of patients with cancer. Modern surgical and radiotherapeutic techniques have markedly reduced the incidence of tumor recurrence in the primary and regional sites; however, overall patient survival rates have not changed significantly over the past 20 years. This lack of improvement in survival rates does not indicate failure of primary treatment modalities; rather, it has emphasized the need for systemic therapy and it has altered our view of the role of surgery and other local treatments in cancer therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Morton DL: Changing concepts of cancer surgery: Surgery as immunotherapy. Am J Surg 135: 367–371, 1978.

    Article  PubMed  CAS  Google Scholar 

  2. Eilber FR, Holmes EC, Morton DL: Immunotherapy as an adjunct to surgery in the treatment of cancer. World J Surg 1: 547–554, 1977.

    Article  PubMed  CAS  Google Scholar 

  3. Veronesi U, Adamus J, et al: Inefficacy of immediate node dissection in Stage I melanoma of the limbs. N Engl J Med 297: 627–630, 1977.

    Article  PubMed  CAS  Google Scholar 

  4. Roses DF, Harris MN, Gumport SL, Michelassi F, Coffey JA, Dubin N: Regional lymph node dissection for malignant melanoma of the extremities. Surgery 89: 654–659, 1981.

    PubMed  CAS  Google Scholar 

  5. Cohen MH, Ketcham AS, et al: Prognostic factors in patients undergoing lymphadenectomy for malignant melanoma. Ann Surg 186: 635–642, 1977.

    Article  PubMed  CAS  Google Scholar 

  6. Holmes EC, Moseley HS, Morton DL, Clark W, Robinson D, Urist MN: A rational approach to the surgical management of melanoma. Ann Surg 186: 481–490, 1977.

    Article  PubMed  CAS  Google Scholar 

  7. Knutson CO, Hori JM, Spratt JS Jr: Melanoma. In: Current problems in surgery. Chicago: Year Book medical Publishers, 1971, pp 1–55.

    Google Scholar 

  8. Nathanson L: Use of BCG in the treatment of human neoplasms: a review. Sem Oncol 1: 337–350, 1974.

    CAS  Google Scholar 

  9. Goodnight JE, Morton DL: Adjuvant immunotherapy. Intl Adv in Surg Oncol 1: 53–83, 1978.

    Google Scholar 

  10. Morton DL, Eilber FR, Malmgren RA, Wood WC: Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery 68: 158–164, 1970.

    PubMed  CAS  Google Scholar 

  11. Morton DL, Eilber FR, Holmes EC, et al: BCG immunotherapy of malignant melanoma: Summary of a 7-year experience. Ann Surg 180: 635–643, 1974.

    Article  PubMed  CAS  Google Scholar 

  12. Nathanson L: Regression of intradermal malignant melanoma after intralesional injection of mycobacterium bovis strain BCG. Cancer Chemother Rep 56: 659–665, 1972.

    PubMed  CAS  Google Scholar 

  13. Pinsky C, Hirshaut Y, Oettgen H: Treatment of malignant melanoma by intratumoral injection of BCG. Proc Am Assoc Cancer Res 13: 21, 1972.

    Google Scholar 

  14. Seigler HF, Shingleton WW, Metzgar RS, et al: Nonspecific and specific immunotherapy in patients with melanoma. Surgery 72: 162–174, 1972.

    PubMed  CAS  Google Scholar 

  15. Eilber FR, Morton DL, Holmes EC, Sparks FC, Ramming KP: Adjuvant immunotherapy with BCG in treatment of regional lymph node metastases from malignant melanoma. N Engl J Med 294: 237–240, 1976.

    Article  PubMed  CAS  Google Scholar 

  16. Gutterman JU, Mavligit G, McBride C, Frei E III, Hersh EM: BCG stimulation of immune responsiveness in patients with malignant melanoma. Cancer 32: 321–327, 1973.

    Article  PubMed  CAS  Google Scholar 

  17. Morton DL, Eilber FR, Holmes EC, Ramming KP: Preliminary results of a randomized trial of adjuvant immunotherapy in patients with malignant melanoma who have lymph node metastases. Aust NZJ Surg 48: 49–52, 1978.

    Article  CAS  Google Scholar 

  18. Paterson AH, Willans D, Jerry LM, McPherson TA: Malignant melanoma (Stage I): A clinical trial of adjuvant BCG immunotherapy. Recent Results in Cancer Res 68: 387–392, 1979.

    Google Scholar 

  19. Cunningham TJ, Schoenfeld D, Nathanson L, A controlled ECOG study of adjuvant therapy in patients with Stage I and II malignant melanoma. In: Program and Abstracts of the Second International Conference on the Adjuvant Therapy of Cancer, Tucson, March 1979.

    Google Scholar 

  20. Pinsky CM, Hirshaut Y, Wanebo HJ, et al: Randomized trial of bacillus Calmette-Guerin (percutaneous administration) as surgical adjuvant immunotherapy for patients with Stage II melanoma. Ann NY Acad Sci 277: 182–192, 1976.

    Article  Google Scholar 

  21. Sparks FC, Silverstein MJ, Hunt JS, Haskell CM, Pilch YH, Morton DL: Complications of BCG immunotherapy in patients with cancer. N Engl J Med 289: 827–830, 1973.

    Article  PubMed  CAS  Google Scholar 

  22. Tripodi D, Parks LC, Brugmans J: Drug-induced restoration of cutaneous delayed hypersensitivity in anergic patients with cancer. N Engl J Med 289: 354–357, 1973.

    Article  PubMed  CAS  Google Scholar 

  23. Rojas AF, Mickiewicz E, Feierstein JN, Glait H, Olivari AJ: Levamisole in advanced human breast cancer. Lancet 1: 211–215, 1976.

    Article  PubMed  CAS  Google Scholar 

  24. Spitler LE, Sagebiel R: A randomized trial of Levamisole versus placebo as adjuvant therapy in malignant melanoma. N Engl J Med 303: 1143–1147, 1980.

    Article  PubMed  CAS  Google Scholar 

  25. Hilal EY, Pinsky CM, Hirshaut Y, Wanebo HJ, et al: Surgical adjuvant therapy of malignant melanoma with Corynebacterium parvum. Cancer 48: 245–251, 1981.

    Article  PubMed  CAS  Google Scholar 

  26. Lawrence B, Lipton A, Harvey H, Corynebacterium parvum vs. BCG as adjuvant immunotherapy for Stage I and II malignant melanoma. In: Program and abstracts of the Second International Conference on the Adjuvant Therapy of Cancer, Tucson, March 1979.

    Google Scholar 

  27. Blume MR, Rosenbaum EH, Cohen RJ, Gershow J, Glassberg AB, Shepley E: Adjuvant immunotherapy of high-risk Stage I melanoma with transfer factor. Cancer 47: 882–888, 1981.

    Article  PubMed  CAS  Google Scholar 

  28. Seigler HF, Cox E, Mutzner F, Shepherd L, Nicholson E, Shingleton WW: Specific active immunotherapy for melanoma. Ann Surg 190: 366–372, 1979.

    Article  PubMed  CAS  Google Scholar 

  29. Aranha GV, McKhann CF, Grage TB, Gunnarsson A, Simmons RL: Adjuvant immunotherapy of malignant melanoma. Cancer 43: 1297–1303, 1979.

    Article  PubMed  CAS  Google Scholar 

  30. Cline M, Haskell C (eds): Cancer chemotherapy, third edition. Philadelphia: WB Saunders, 1980, p 380.

    Google Scholar 

  31. Fisher B, Carbone P, et al: L-phenylalanine mustard (L-PAM) in the management of primary breast cancer. N Engl J Med 292: 117–122, 1975.

    Article  PubMed  CAS  Google Scholar 

  32. Bonadonna G, Bursamolino E, et al: Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 294: 405–410, 1976.

    Article  PubMed  CAS  Google Scholar 

  33. Seigler HF, Lucas VS, Pickett NJ, Huang AT: DTIC, CCNU, Bleomycin, and Vincristine (BOLD) in metastatic melanoma. Cancer 56: 2346–2348, 1980.

    Article  Google Scholar 

  34. Hill GJ II, Moss SE, Golumb FM, Grage TB, Fletcher WS, Minton JP, Krementz ET: DTIC and combination therapy for melanoma: III. DTIC (NSC 45388) Surgical Adjuvant Study COG Protocol 7040. Cancer 47: 2556–2562, 1981.

    Article  PubMed  Google Scholar 

  35. Golomb FM, Bromberg J, Dubin N: A controlled study of the survival experience of patients with primary malignant melanoma of the distal extremities treated with adjuvant isolated perfusion. Proceeding of the Second International Conference on Adjuvant Therapy of Cancer, Tucson, Arizona, March 1979. In: Adjuvant therapy of cancer II, Jones SE, Salmon SE (eds). New York: Grune and Stratton, 1979, pp 519–526.

    Google Scholar 

  36. Cunningham TJ, Schoenfeld D, Nathanson L, Wolter J, et al: A controlled ECOG study of adjuvant therapy in patients with Stage I and II malignant melanoma. Proceedings of the Second International Conference on Adjuvant Therapy of Cancer, Tucson, Arizona, March 1979. In: Adjuvant therapy of Cancer II, Jones SE, Salmon SE (eds). New York: Grune and Stratton, 1979, pp 507–517.

    Google Scholar 

  37. Holtermann OA, Karakousis CP, Berger J, Constantine RI: Adjuvant therapy with DTIC and Estracyt or BCG in malignant melanoma. Proc Am Soc Clin Ocol 21: 400, 1980.

    Google Scholar 

  38. Quagliana J, Tranum B, Neidhardt J, Gagliano R: Adjuvant chemotherapy with BCNU, Hydrea and DTIC (BHD) with or without immunotherapy (BCG) in High-risk melanoma patients: An SWOG study. Proc Am Soc Clin Ocol 21: 399, 1980.

    Google Scholar 

  39. Sterchi JM, Cole W, Richards F, et al: Dacarbazine (DTIC) and immunotherapy with the methanol extraction residue of BCG (MER) in Stage II and Stage III melanoma. Proc Am Soc Clin Ocol 21: 363, 1980.

    Google Scholar 

  40. Karakousis CP, Didolkar MS, Lopez R, Baffi R, Moore R, Holyoke ED: Chemoimmuno-therapy (DTIC and Corynebacterium parvum) as adjuvant treatment in malignant melanoma. Cancer Treat Rep 63: 1739–1743, 1979.

    PubMed  CAS  Google Scholar 

  41. Veronesi U, Beretta G: Controlled study for prolonged chemotherapy, immunotherapy, and chemotherapy plus immunotherapy as an adjuvant to surgery in malignant melanoma (Trial 6): Preliminary report. Recent results Cancer Res 68: 375–379, 1979.

    Google Scholar 

  42. Veronesi U, Adamus J, Aubert C, et al: A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med 307: 913–916, 1982.

    Article  PubMed  CAS  Google Scholar 

  43. Kaufman SD, Cosimi AB, Wood WC, Carey RW: Adjuvant therapy in malignant melanoma: A trial of immunotherapy, chemotherapy, and combined treatment. Recent Results Cancer Res 68: 380–386, 1979.

    Google Scholar 

  44. Banzet P, Jacquillat C, Maral J: Adjuvant chemotherapy (CX) with or without immunotherapy (I) for malignant melanoma with metastatic nodes (MMMN). Proc Am Assoc Cancer Res 20: 333, 1979.

    Google Scholar 

  45. Patt YZ, Hersh EM, Schafer LA, et al: Clinical and immunological evaluation of the use of thymosin plus BCG +/- DTIC in the adjuvant treatment of Stage IIIB melanoma. Prog Cancer Res Ther 7: 357–371, 1978.

    Google Scholar 

  46. Morton DL, Unpublished data.

    Google Scholar 

  47. Creagan ET, Cupps RE, Ivins JC, et al: Adjuvant radiation therapy for regional nodal metastases from malignant melanoma. Cancer 42: 2206–2210, 1978.

    Article  PubMed  CAS  Google Scholar 

  48. Karakousis CP, Lopez R, Bhakoo HS, Rosen F, Moore R: Steroid hormone receptors and tamoxifen treatment in malignant melanoma. Proc Am Soc Clin Ocol 21: 345, 1980.

    Google Scholar 

  49. Wang BS, Steele G, Mannick JA: Therapeutic effect of immune ribonucleic acid in an adjuvant setting: Prevention of pulmonary metastases after primary melanoma resection. Surg Forum 29: 124–126, 1978.

    PubMed  CAS  Google Scholar 

  50. Mastrangelo MJ, Clark WH Jr, Bellet RE, Berd D: Cutaneous malignant melanoma: diagnosis, prognosis, and conventional medical therapy. In: Immunotherapy of cancer: Present status of trials in man, Terry WD, Windhorst D (eds). New York: Raven Press, 1978, pp 1–17.

    Google Scholar 

  51. Terry WD: Immunotherapy of malignant melanoma. N Engl J Med 303: 1174–1175, 1980.

    Article  PubMed  CAS  Google Scholar 

  52. Aleong J, Bartlett DE: Improved graphs for calculating sample sizes when comparing two independent binomial distributions. Biometrics 35: 875–881, 1979.

    Article  Google Scholar 

  53. Morton DL, Unpublished data.

    Google Scholar 

  54. Day CL, Sober AJ, Lew RA, et al: Malignant melanoma patients with positive nodes and relatively good prognosis: Microstaging retains prognostic significance in clinical Stage I melanoma patients with metastases to regional nodes. Cancer 47: 955–962, 1981.

    Article  PubMed  Google Scholar 

  55. Balch CM, Soong SJ, Murad TM, Ingalls AL, Maddox WA: A multifactorial analysis of melanoma. III. Prognostic factors in melanoma patients with lymph node metastases (Stage II). Ann Surg 193: 377–388, 1981.

    Article  PubMed  CAS  Google Scholar 

  56. Huth JF, Gupta RK, Morton DL: The relationship of tumor-associated urinary antigens to disease recurrence in melanoma patients. Surg Forum, 32: 417–419, 1981.

    Google Scholar 

  57. Salmon WE, Hamburger AW, Soehnlen B, Durie BGM, Alberts DS, Moon TE: Quantitation of differential sensitivity of human tumor stem cells to anticancer drugs. N Engl J Med 298: 1321–1327, 1978.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Allan W. Silberman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Donald L. Morton
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Cancer Center, Division of Hematology/Oncology, University of Texas Medical Branch, 77550, Galveston, TX, USA

    John J. Costanzi M.D. (Professor of Medicine) (Professor of Medicine)

Rights and permissions

Reprints and permissions

Copyright information

© 1983 Martinus Nijhoff Publishers, The Hague/Boston/London

About this chapter

Cite this chapter

Silberman, A.W., Morton, D.L. (1983). Adjuvant Therapy Following Surgery for Primary Malignant Melanoma. In: Costanzi, J.J. (eds) Malignant Melanoma 1. Cancer Treatment and Research, vol 9. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-3900-7_10

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-3900-7_10

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-3902-1

  • Online ISBN: 978-1-4613-3900-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation